Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/9522
Citations | ||
Scopus | Web of ScienceĀ® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Cyclooxygenase inhibitors: any reservations? |
Author: | Penglis, P. James, M. Cleland, L. |
Citation: | Internal Medicine Journal, 2001; 31(1):37-41 |
Publisher: | Blackwell Science Asia |
Issue Date: | 2001 |
ISSN: | 1444-0903 1445-5994 |
Abstract: | The discovery of two cyclooxygenase isozymes, constitutive COX-1 and inducible COX-2, has resulted in the rapid development of selective inhibitors of COX-2, such as celecoxib and rofecoxib. Compared with traditional non-steroidal anti-inflammatory drug agents, use of COX-2 selective inhibitors is associated with decreased incidence of adverse gastric events as a result of minimal inhibition of gastroprotective COX-1, but with equivalent anti-inflammatory benefit through inhibition of COX-2. However, there is evidence to suggest that the 'COX-1 = constitutive, COX-2 = inflammatory' paradigm is less distinct than originally proposed. Futhermore, selective COX-2 inhibitors may have other consequences as a result of the change in the eicosanoid profile. Thus, despite the relatively safe gastrointestinal profile, vigilant post-marketing surveillance for other adverse effects is required. |
Keywords: | Animals Humans Mice Inflammation Isoenzymes Eicosanoids Tumor Necrosis Factor-alpha Cytokines Cyclooxygenase Inhibitors Prostaglandin-Endoperoxide Synthases |
DOI: | 10.1046/j.1445-5994.2001.00002.x |
Published version: | http://dx.doi.org/10.1046/j.1445-5994.2001.00002.x |
Appears in Collections: | Aurora harvest Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.